Decibel Therapeutics Expands World-Class Scientific Advisory Board
May 24, 2021 16:15 ET
|
Decibel Therapeutics, Inc.
BOSTON, May 24, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Decibel Therapeutics to Present at the UBS Global Healthcare Virtual Conference
May 19, 2021 08:00 ET
|
Decibel Therapeutics, Inc.
BOSTON, May 19, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Decibel Therapeutics Reports First Quarter 2021 Financial Results and Corporate Update
May 13, 2021 17:05 ET
|
Decibel Therapeutics, Inc.
– Established cGMP manufacturing and development agreement with Catalent for otoferlin dual-vector gene therapy, DB-OTO – – Successfully completed the second tranche of an oversubscribed Series D...
Decibel Therapeutics to Present at the American Society of Gene and Cell Therapy 24th Annual Meeting
April 28, 2021 08:00 ET
|
Decibel Therapeutics, Inc.
BOSTON, April 28, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore...
Decibel Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
April 08, 2021 08:00 ET
|
Decibel Therapeutics, Inc.
BOSTON, April 08, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore...
Decibel Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update
March 29, 2021 16:05 ET
|
Decibel Therapeutics, Inc.
-Successfully completed an oversubscribed Series D financing and upsized Initial Public Offering raising approximately $220.1M in gross proceeds- -Established development and manufacturing agreement...
Decibel Therapeutics Added to Russell 2000 Index
March 22, 2021 08:00 ET
|
Decibel Therapeutics, Inc.
BOSTON, March 22, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX) (“Decibel”), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments...
Decibel Therapeutics to Present at the Barclays Global Healthcare Conference
March 04, 2021 08:00 ET
|
Decibel Therapeutics, Inc.
BOSTON, March 04, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore...
Decibel Therapeutics Presents Promising Preclinical Findings on DB-OTO, Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin Mutations
February 24, 2021 07:00 ET
|
Decibel Therapeutics, Inc.
BOSTON, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage company developing treatments to restore and improve hearing and balance, presented preclinical data...
Decibel Therapeutics to Present at the 44th Annual Association for Research in Otolaryngology (ARO) Conference
February 19, 2021 07:00 ET
|
Decibel Therapeutics, Inc.
BOSTON, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...